Human B7-2/CD86 Fluorescein-conjugated Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of B7‑2/CD86 in Human Blood Monocytes by Flow Cytometry. Human peripheral blood monocytes were stained with Mouse Anti-Human CD14 APC-conjugated Monoclonal Antibody (Catalog # FAB3832A) and either (A) Mouse Anti-Human B7-2/CD86 Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB141F) or (B) Mouse IgG1Fluorescein Isotype Control (Catalog # IC002F). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
Background: B7-2/CD86
B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant costimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. Human B7-2 is a 329 amino acid (aa) protein containing a putative 23 aa signal peptide, a 224 aa extracellular domain, a 21 aa transmembrane domain, and a 61 aa cytoplasmic domain. Human B7-2 and B7-1 share 26% amino acid identity. Human and mouse B7-2 share 50% amino acid identity. However, it has been observed that both human and mouse B7‑1 and B7‑2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
- Azuma, M. et al. (1993) Nature 366:76.
- Freeman, G.J. et al. (1993) Science 262:909.
- Freeman, G. et al. (1991) J. Exp. Med. 174:625.
- Selvakumar, A. et al. (1993) Immunogenetics 38:292.
- Chen, C. et al. (1994) J. Immunol. 152:4929.
- Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.
Product Datasheets
Citations for Human B7-2/CD86 Fluorescein-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell‑dendritic cell‑based vaccine
Authors: Mona S Abdellateif, Sabry M Shaarawy, Eman Z Kandeel, Ahmed H El‑Habashy, Mohamed L Salem, Motawa E El‑Houseini
Oncology Letters
-
NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells.
Authors: Kraetzel K, Stoelcker B, Eissner G, Multhoff G, Pfeifer M, Holler E, Schulz C
Eur. Respir. J., 2008-04-16;32(3):563-70.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human B7-2/CD86 Fluorescein-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human B7-2/CD86 Fluorescein-conjugated Antibody and earn rewards!
Have you used Human B7-2/CD86 Fluorescein-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
